BioCryst Pharmaceuticals, Inc. (BCRX) Forms $5.62 Double Bottom; 6 Analysts Are Bullish The Chemours Company (CC) Last Week

BioCryst Pharmaceuticals, Inc. (BCRX) formed double bottom with $5.28 target or 6.00% below today’s $5.62 share price. BioCryst Pharmaceuticals, Inc. (BCRX) has $553.04 million valuation. The stock decreased 0.71% or $0.04 during the last trading session, reaching $5.62. About 794,377 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since January 15, 2017 and is uptrending. It has outperformed by 58.38% the S&P500.

Among 8 analysts covering Chemours (NYSE:CC), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Chemours had 33 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of The Chemours Company (NYSE:CC) has “Positive” rating given on Friday, February 17 by Susquehanna. The rating was maintained by Citigroup with “Neutral” on Monday, April 18. The stock of The Chemours Company (NYSE:CC) has “Hold” rating given on Thursday, September 1 by Jefferies. The firm has “Buy” rating by Susquehanna given on Monday, January 8. As per Monday, May 15, the company rating was maintained by Susquehanna. JP Morgan upgraded the stock to “Neutral” rating in Friday, August 7 report. The stock of The Chemours Company (NYSE:CC) earned “Hold” rating by Goldman Sachs on Wednesday, December 6. The firm earned “Overweight” rating on Friday, May 12 by JP Morgan. The firm has “Buy” rating by Jefferies given on Friday, June 16. The company was downgraded on Monday, December 12 by Goldman Sachs. See The Chemours Company (NYSE:CC) latest ratings:

08/01/2018 Broker: Susquehanna Rating: Buy New Target: $72.0 Maintain
06/12/2017 Broker: Goldman Sachs Rating: Hold New Target: $55.0 Downgrade
06/11/2017 Broker: Barclays Capital Rating: Overweight Old Target: $55 New Target: $58 Maintain
03/11/2017 Broker: UBS Rating: Neutral Old Target: $50 New Target: $59 Maintain
10/10/2017 Broker: Jefferies Rating: Buy New Target: $60.0 Maintain
06/09/2017 Broker: Jefferies Rating: Buy New Target: $60.0 Maintain
07/08/2017 Broker: UBS Old Rating: Sell New Rating: Neutral New Target: $50 Upgrade
04/08/2017 Broker: Barclays Capital Rating: Buy New Target: $55.0000

Since September 18, 2017, it had 0 buys, and 1 sale for $294,035 activity. $294,035 worth of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares were sold by Cohen Fred E.

Among 14 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. BioCryst Pharmaceuticals had 33 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Tuesday, February 9. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Hold” rating by Jefferies on Wednesday, September 9. As per Tuesday, August 8, the company rating was maintained by Noble Financial. The firm has “Neutral” rating given on Tuesday, February 9 by JP Morgan. The firm has “Outperform” rating by FBR Capital given on Tuesday, February 9. On Wednesday, September 6 the stock rating was upgraded by J.P. Morgan to “Buy”. The company was downgraded on Tuesday, February 9 by Needham. The rating was maintained by H.C. Wainwright on Tuesday, August 8 with “Buy”. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Buy” rating by Noble Financial on Friday, May 26. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Buy” rating by H.C. Wainwright on Wednesday, November 8.

Analysts await BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings on February, 26. They expect $-0.15 earnings per share, down 150.00% or $0.09 from last year’s $-0.06 per share. After $-0.18 actual earnings per share reported by BioCryst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -16.67% EPS growth.

Investors sentiment increased to 1.69 in Q3 2017. Its up 0.01, from 1.68 in 2017Q2. It increased, as 12 investors sold BioCryst Pharmaceuticals, Inc. shares while 24 reduced holdings. 28 funds opened positions while 33 raised stakes. 79.80 million shares or 20.47% more from 66.24 million shares in 2017Q2 were reported. Vanguard invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Wells Fargo Mn holds 96,671 shares or 0% of its portfolio. Franklin Street Advisors Nc holds 49,000 shares or 0.04% of its portfolio. Pura Vida Ltd Company holds 0.39% or 150,000 shares. Emory University has 1.49% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 360,042 shares. Baker Bros Advsrs L P holds 0.59% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 14.00M shares. Deerfield Management stated it has 1.17% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Oberweis Asset Mngmt has 0.03% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Gsa Capital Prtnrs Llp has invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Sg Americas Securities Limited Liability Co invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Clarivest Asset Management Ltd Liability Co, a California-based fund reported 74,700 shares. 38,923 are owned by Susquehanna Interest Grp Llp. Tudor Corp Et Al, Connecticut-based fund reported 102,494 shares. 128,045 are owned by California State Teachers Retirement System. 500,000 are held by Ghost Tree Cap Ltd Company.

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The company has market cap of $9.72 billion. It operates through three divisions: Titanium Technologies, Fluoroproducts, and Chemical Solutions. It has a 34.47 P/E ratio. The Titanium Technologies segment makes and sells titanium dioxide under the Ti-Pure brand name to deliver whiteness, brightness, opacity, and protection in various applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, PVC window profiles, laminate papers, and coated papers and paperboards used for packaging.